What Is Driving the Adalimumab Market Size and Forecast Through 2035

What Is Driving the Adalimumab Market Size and Forecast Through 2035?

The adalimumab market represents one of the most significant segments in the global biologics and autoimmune therapeutics industry. Adalimumab, originally marketed as HUMIRA by AbbVie, has become a cornerstone treatment for autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis. With the patent expirations paving the way for biosimilars and the global rise in autoimmune conditions, understanding the adalimumab market size and forecast is critical for investors, analysts, and business decision-makers.

In 2025, the global adalimumab market size is valued at USD 10.98 billion and is projected to grow at a CAGR of 6.20%, reaching USD 20.04 billion by 2035. The market's strategic importance lies in its broad clinical indications, biosimilar opportunities, and long-term growth driven by chronic disease prevalence.

Market Overview: What Is the Current Scope of the Adalimumab Market?

The adalimumab market encompasses branded biologics and biosimilar products used to treat a variety of autoimmune and inflammatory disorders. Adalimumab functions as a TNF-alpha inhibitor, administered mainly via subcutaneous injection, and often prescribed for long-term therapy.

Key Market Snapshot

Market Size (2025): USD 10.98 Billion
Forecast (2035): USD 20.04 Billion
CAGR (2025–2035): 6.20%
Therapeutic Use: Autoimmune and inflammatory conditions
Market Dynamics: Transition from branded biologics to biosimilars

What Are the Key Growth Drivers in the Adalimumab Market?

1. Rising Prevalence of Autoimmune Diseases

Global prevalence of autoimmune disorders is increasing due to:

Aging population trends
Environmental and lifestyle factors
Improved diagnosis and awareness

Key implications: Chronic conditions such as rheumatoid arthritis and Crohn’s disease require long-term treatment, ensuring sustained adalimumab demand.

2. Broad Clinical Indications

Adalimumab is approved for multiple indications, including:

Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Chronic Plaque Psoriasis
Crohn’s Disease
Ulcerative Colitis

Benefit: Diversified applications reduce reliance on a single therapeutic area.

3. Patent Expirations and Biosimilar Launches

With the expiration of HUMIRA patents globally:

Biosimilar manufacturers have entered the market
Treatment costs have decreased
Patient access has expanded in emerging markets

Outcome: Volume-driven growth offsets branded revenue decline.

4. Expanding Healthcare Infrastructure

Emerging economies are increasing:

Specialty clinics and hospitals
Biologic reimbursement schemes
Cold-chain and logistics infrastructure

This supports higher adoption of advanced biologics.

What Emerging Trends Are Shaping the Adalimumab Market?

Shift Toward Biosimilars

Aggressive pricing strategies by biosimilar manufacturers
Increased regulatory support and substitution policies
Physician confidence in biosimilar efficacy

Formulation and Delivery Innovations

High-concentration, low-volume injections
Citrate-free formulations to reduce injection-site pain
User-friendly autoinjectors improving adherence

Growth of Online and Specialty Pharmacies

Convenient chronic therapy refill options
Telehealth and digital adherence programs
Expansion in direct-to-patient distribution channels

Market Segmentation: How Is the Adalimumab Market Structured?

By Indication

Rheumatoid Arthritis
Ankylosing Spondylitis
Chronic Plaque Psoriasis
Crohn’s Disease
Ulcerative Colitis
Psoriatic Arthritis
Others

Insight: Rheumatoid arthritis dominates due to high prevalence and long-term treatment needs.

By Type

Biologics
Biosimilars
- Adalimumab-ATTO
- Adalimumab-BWWD
- Adalimumab-ADBM
- Adalimumab-ADAZ
- Adalimumab-FKJP
- Adalimumab-AFZB
- Others

Fastest growing segment: Biosimilars due to regulatory encouragement and cost advantages.

By Dosage Strength

40MG/0.4ML
80MG/0.8ML
20MG/0.4ML
10MG/0.1ML
Others

Standard dosage: 40MG/0.4ML used widely across indications.

By Drug Type

Branded
Generics
- Amjevita
- Hyrimoz
- Hulio
- Others

By Route of Administration

Parenteral
Oral
Others

Primary route: Parenteral, given biologic characteristics.

By Distribution Channel

Hospital-Based Pharmacies
Retail Pharmacies
Online Pharmacies

Observation: Hospital-based channels dominate due to specialist prescribing.

Regional Insights: Where Are Adalimumab Market Growth Opportunities?

North America

Largest regional market
High biologic adoption
Strong insurance coverage
Early biosimilar adoption post-patent expiry

Europe

Mature, price-competitive market
Strong biosimilar adoption via tenders
High patient and physician awareness

Asia Pacific

Fastest-growing region
Expanding patient base
Rising healthcare expenditure and biosimilar production

Latin America

Gradual adoption of biosimilars
Improving regulatory frameworks
Expanding hospital infrastructure

Middle East & Africa

Private healthcare investment
Increasing availability of specialty treatments

Competitive Landscape: Who Are the Key Players in the Adalimumab Market?

The adalimumab market is highly competitive, driven by biosimilar proliferation.

Companies Covered

AbbVie Inc.
Amgen Inc.
Fresenius Kabi AG
Celltrion Healthcare Co. Ltd.
Alvotech Ehf.
Bio-Thera Solutions Ltd.
Zydus Lifesciences Limited
Hetero Healthcare Ltd.
Innovent Biologics, Inc.
Novartis International AG (Sandoz)
Reliance Life Sciences Pvt. Ltd.
Samsung C&T Corporation
Terumo Corp.
Torrent Pharmaceuticals Ltd.

Strategies Adopted

Competitive pricing and tendering
Regional licensing and co-marketing agreements
Portfolio expansion beyond TNF inhibitors

Challenges and Restraints in the Adalimumab Market

Pricing and Margin Pressures

Biosimilar entry reduces average selling prices
Government-mandated price caps in some regions

Regulatory Hurdles

Complex approval pathways for biosimilars
Limited interchangeability in certain markets

Physician and Patient Hesitancy

Brand loyalty to originator biologics
Concerns about immunogenicity and efficacy

Future Market Outlook: Where Is Adalimumab Headed?

Opportunities

High growth potential in emerging markets
Development of patient-centric biosimilar formulations
Strategic collaborations and regional manufacturing partnerships

Long-Term Perspective

Declining branded revenues offset by biosimilar volume growth
Sustained role as a first-line TNF inhibitor
Market expansion through increased access and affordability

Discover More Reports

Antimicrobial Hospital Curtains Market

Mastopexy Market

Gas Chromatography Market

Guidewires Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: [email protected]
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com